Evidence map›Paper›PMID 19371627›Full record

ArticleToxicology and applied pharmacology2009

Chromium reduces the in vitro activity and fidelity of DNA replication mediated by the human cell DNA synthesome.

Heqiao Dai, Jianying Liu, Linda H Malkas, Jennifer Catalano, Srilakshmi Alagharu, Robert J Hickey

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Novel method of removing metals from estuarine water using whole microbial mats.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Heqiao DaiDepartment of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, Indiana University Cancer Research Institute, 1044 W. Walnut Street R4-170 Indianapolis, IN 46202, USA.
Jianying Liu
Linda H Malkas
Jennifer Catalano
Srilakshmi Alagharu
Robert J Hickey
Cancer Research Institute · USIndiana University – Purdue University Indianapolis · US

Funding

A Structure/function Analysis of a Tumor Specific ProteinR01CA121289 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI MALKAS, LINDA H. · 2007 to 2011
$1.5M
UNIQUE MODEL FOR EVALUATING ANTICANCER DRUGSR01CA057350 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MALKAS, LINDA H · 1993 to 2004
$1.3M
DEVELOPMENT AND EVALUATION OF A NOVEL CANCER BIOMARKERR01CA083199 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MALKAS, LINDA H · 1999 to 2003
$1.3M
REGULATION OF THE BREAST CELL DNA SYNTHESOMER01CA074904 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI HICKEY, ROBERT J · 1998 to 2000
$197k
NCI NIH HHS R01 CA057350NCI NIH HHS R01 CA074904NCI NIH HHS R01 CA083199NCI NIH HHS R01 CA121289NCI NIH HHS R01 CA57350NCI NIH HHS R01 CA74904
6 · The paper itself

Abstract

Hexavalent chromium Cr(VI) is known to be a carcinogenic metal ion, with a complicated mechanism of action. It can be found within our environment in soil and water contaminated by manufacturing processes. Cr(VI) ion is readily taken up by cells, and is recognized to be both genotoxic and cytotoxic; following its reduction to the stable trivalent form of the ion, chromium(Cr(III)), within cells. This form of the ion is known to impede the activity of cellular DNA polymerase and polymerase-mediated DNA replication. Here, we report the effects of chromium on the activity and fidelity of the DNA replication process mediated by the human cell DNA synthesome. The DNA synthesome is a functional multiprotein complex that is fully competent to carry-out each phase of the DNA replication process. The IC(50) of Cr(III) toward the activity of DNA synthesome-associated DNA polymerases alpha, delta and epsilon is 15, 45 and 125 muM, respectively. Cr(III) inhibits synthesome-mediated DNA synthesis (IC(50)=88 muM), and significantly reduces the fidelity of synthesome-mediated DNA replication. The mutation frequency induced by the different concentrations of Cr(III) ion used in our assays ranges from 2-13 fold higher than that which occurs spontaneously, and the types of mutations include single nucleotide substitutions, insertions, and deletions. Single nucleotide substitutions are the predominant type of mutation, and they occur primarily at GC base-pairs. Cr(III) ion produces a lower number of transition and a higher number of transversion mutations than occur spontaneously. Unlike Cr(III), Cr(VI) ion has little effect on the in vitro DNA synthetic activity and fidelity of the DNA synthesome, but does significantly inhibit DNA synthesis in intact cells. Cell growth and proliferation is also arrested by increasing concentrations of Cr(VI) ion. Our studies provide evidence indicating that the chromium ion induced decrease in the fidelity and activity of synthesome mediated DNA replication correlates with the genotoxic and cytotoxic effects of this metal ion; and promotes cell killing via inhibition of the DNA polymerase activity mediating the DNA replication and repair processes utilized by human cells.

Indexed as

Cell CycleChromiumDNADNA-Directed DNA PolymeraseDNA ReplicationDose-Response Relationship, DrugEnvironmental PollutantsHeLa CellsHumansMultienzyme ComplexesReplisomesTime FactorsChromiumDNADNA-Directed DNA PolymeraseEnvironmental PollutantsMultienzyme ComplexesReplisomes

Identifiers

PMID19371627
PMCPMC2804861
OpenAlexW2039096849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.